These data may explain the encouraging but limited response rates of cSCC to single agent cepilimumab anti-PD1 treatment30,31 and suggests that combination checkpoint inhibition may enhance therapeutic responses. Here, PDCD1 is linked to skin squamous cell carcinoma.